The sustained-release formulation of nifedipine is commonly used to address major cardiovascular conditions, encompassing Essential Hypertension and the symptomatic management of Angina Pectoris (Chronic Stable Angina and Vasospastic Angina). The primary purpose is to help maintain a sense of stability when symptoms are more noticeable, which contributes to easing the overall symptom load.

These therapeutic applications are applied in clinical scenarios that require long-term management of symptoms related to systemic imbalance and heightened physiological activity.

“The sustained-release format assists in providing ongoing support for symptoms associated with chronic conditions, which helps patients cope more steadily with symptom fluctuations.”

Quick Fact: Supports Management of Recurrent Chest Pain and Elevated Blood Pressure

Who Can and Cannot Use Fedaloc SR?

Eligibility for using Fedaloc SR (Nifedipine Sustained-Release) is strictly defined by regulatory authorities based on population safety data and specific health conditions. The medicine is approved for use in adults (18 years and older).

---

Absolute Non-Eligibility (Contraindications)

Fedaloc SR is contraindicated in several groups, meaning use must be strictly avoided. This includes patients with known hypersensitivity to Nifedipine or other dihydropyridines. It is also prohibited in cases of acute cardiovascular instability, such as cardiogenic shock, unstable angina, and within one month of an acute myocardial infarction.

Due to its sustained-release design, the medicine is also contraindicated in patients with a history of gastrointestinal or esophageal obstruction.

---

Populations Requiring Restricted Use

Use requires special caution and monitoring in patients with impaired liver function, as reduced clearance may lead to increased medicine levels. Caution is also advised for patients with severe hypotension (very low blood pressure) and those with impaired left ventricular function.

Regulatory agencies do not recommend use in the pediatric population (under 18 years) because safety and efficacy have not been established. Use during pregnancy and lactation is also generally not recommended or is restricted to highly specialized, unresponsive conditions.

The official regulatory profile for Fedaloc SR defines interaction patterns primarily through the metabolism of the active ingredient Nifedipine by the CYP3A4 enzyme system.

Contraindicated Combinations

Co-administration with strong inducers of the CYP3A4 enzyme, such as the antibiotic Rifampicin or the herbal product St. John’s Wort, is formally prohibited. This restriction is based on the documented effect of these substances causing a severe reduction in Nifedipine plasma concentrations.

Pharmacokinetic and Pharmacodynamic Effects

Interacting Substance Category	Documented Outcome	Classification
CYP3A4 Inhibitors (e.g., Itraconazole, Erythromycin, Protease Inhibitors)	Increased Nifedipine plasma concentrations (exposure).	Pharmacokinetic Interaction
Grapefruit / Grapefruit Juice	Avoidance required; significantly increases Nifedipine exposure.	Pharmacokinetic Interaction
Beta-blocking Agents	Risk of additive hypotensive effect.	Pharmacodynamic Interaction
Digoxin	Elevated serum concentrations of Digoxin upon co-administration.	Transporter-Mediated Effect

Co-administration with other CYP3A4 inducers (e.g., Phenytoin, Carbamazepine) reduces Nifedipine exposure. Specific regulatory cautions also apply to co-administration with Intravenous Magnesium Sulphate in pregnant women. Population-specific notes indicate that patients with hepatic impairment may be more susceptible to exposure-related interactions due to altered Nifedipine clearance.

Targeting the L-Type Calcium Gate

Fedaloc SR's active ingredient, Nifedipine, functions as a highly selective inhibitor of the L-type voltage-gated calcium channels ( Ca V1.2) found predominantly in artery walls. By binding to and stabilizing the channel in its inactivated state, Nifedipine physically blocks the influx of extracellular calcium ions ( Ca^2+), thereby halting the molecular signal needed for vascular smooth muscle contraction.

---

Lowering Systemic Vascular Resistance (SVR)

This cellular relaxation cascade leads to widespread vasodilation (widening) of the peripheral arteries. This physiological change reduces the friction and opposition to blood flow, known as the Systemic Vascular Resistance. The resultant decrease in SVR decreases the mechanical force (afterload) exerted on the heart. The Sustained-Release (SR) formulation is a mechanistic feature designed to ensure this reduction in SVR is gradual, mitigating the rapid pressure change that could otherwise trigger a strong baroreceptor reflex compensation.

---

️ The Dynamic Mechanistic Balance

While the sustained action produces a sustained alteration in the physiological system, the fundamental process of lowering SVR engages the body's intrinsic regulatory feedback systems. This mechanistic limitation means the body may initiate a compensatory reflex sympathetic activation which, as a physiological response, can attempt to counteract the drug's effect by increasing the heart rate (reflex tachycardia).

Administration Principles

Fedaloc SR (Nifedipine Sustained-Release) is indicated for oral administration as a once-daily tablet. The specialized sustained-release design dictates that the tablet must be swallowed whole and intact with a glass of water; it must not be crushed, chewed, or divided. This integrity must be maintained to ensure the active ingredient is released slowly and consistently over a 24-hour period, supporting the long-term usage pattern of the medicine. The medication may be taken with or without food, as its administration in the presence of a meal does not typically influence the overall extent of absorption.

---

Dosing and Regulatory Schedule

The usage schedule for adults typically includes a starting dose for maintenance of 30 mg to 60 mg once daily. Maintenance doses generally range between 30 mg and 90 mg, with the maximum daily dose extending up to 120 mg for certain formulations. Any dose adjustments should be made gradually, often over intervals of 7 to 14 days, to ensure proper physiological adaptation to the change. When discontinuing treatment, the dosage must also be decreased gradually under clinical supervision.

---

Population-Specific Usage Constraints

Usage considerations apply to certain patient populations. For older adults and patients with hepatic impairment (compromised liver function), treatment initiation at the lowest available dose (e.g., 30 mg) is often considered to account for reduced drug clearance. Conversely, for patients undergoing renal dialysis, no supplemental dose is typically required. It is also noted that using multiple lower-strength sustained-release tablets may not be directly substituted for a single higher-strength tablet.

Research Evidence / Overview of Studies for Fedaloc SR

This overview describes the types of clinical research conducted on Fedaloc SR (Nifedipine Sustained-Release) and the scope of the evidence available, focusing only on the patterns observed in group studies. Research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

---

Evidence for Use in Managing Essential Hypertension (High Blood Pressure)

The research base for high blood pressure includes Randomized Controlled Trials (RCTs). These studies were structured to compare the sustained-release formulation against other medicines and placebo in adult patients. These trials are often combined into Meta-analyses to examine all reported patterns across the research landscape.

Researchers monitored outcomes related to systemic or functional imbalance, specifically monitored changes in Systolic and Diastolic Blood Pressure (SBP/DBP) measures. Studies also monitored the formulation's performance in achieving sustained blood pressure measurements over a full 24-hour cycle. Long-term research also included trials designed to monitor outcomes related to definitive cardiovascular events.

---

Evidence for Symptomatic Management of Angina Pectoris (Chest Pain)

Researchers explored the sustained-release formulation's application in conditions characterized by fluctuating or episodic manifestations, specifically Chronic Stable Angina and Vasospastic Angina. The research includes multiple Randomized Controlled Trials (RCTs).

In these trials, researchers tracked key patient-reported outcomes such as the frequency of angina episodes and the patients' exercise tolerance in an effort to assess outcomes related to episodic or acute changes. Studies report how symptoms evolved in the observed populations, noting measurements of change in the frequency of chest pain events.

Official summaries have noted that the confirmation of sustained effect over a very long period for all aspects of angina symptom relief was an area requiring continued investigation. Furthermore, research exploring certain short-term symptom changes sometimes involves findings that were mixed, meaning information for long-term outcomes is limited based on those specific trials.

---

What is Still Uncertain in the Research Landscape

This section highlights the documented limitations in the body of research for Fedaloc SR:

• Information for long-term outcomes is limited for all specific outcomes, as follow-up durations were limited in some of the initial efficacy trials.
• Data for certain groups remain insufficient, with limited information available regarding outcomes for some rare or complex patient populations.
• The research provides context but not individual predictions, and evidence highlights what is known — and what is still uncertain — within the scientific community.

Common questions about Fedaloc SR (FAQ)

---

Q: Why is Fedaloc SR not recommended for pregnant women?

Official regulatory documents indicate that there are no sufficient studies on the use of Nifedipine sustained-release in pregnant women. Animal studies have shown that the drug can potentially cause harm to the developing fetus. Regulatory information indicates that the drug is generally not recommended during pregnancy, and some official labels list its use as contraindicated.

---

Q: What happens if I take Fedaloc SR with grapefruit or grapefruit juice?

Official product information states that the use of grapefruit or grapefruit juice is contraindicated or required to be avoided while taking Fedaloc SR. This is because grapefruit can significantly increase the concentration of the medicine in the blood. This increased level may raise the risk of experiencing common side effects like headaches, flushing, and significant drops in blood pressure.

---

Q: How does Fedaloc SR actually work to lower blood pressure?

Fedaloc SR works by acting as a peripheral arterial vasodilator. This means the active ingredient, Nifedipine, relaxes the smooth muscle walls of your arteries, causing them to widen. This widening action reduces the resistance that blood encounters as it flows through the body, which in turn reduces the overall arterial blood pressure.

---

Q: If I miss a dose of Fedaloc SR, what should I do?

The official patient labeling addresses missed doses for this once-daily tablet. It states that a missed dose should be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose (e.g., within 12 hours), the individual should skip the missed dose and resume the regular schedule. The labeling emphasizes that a double dose should not be taken to compensate for a missed dose.

---

Q: Can I drink alcohol while taking Fedaloc SR?

Official product labeling indicates that alcohol consumption should be approached with caution as it may increase the risk of certain side effects. Alcohol can lower blood pressure, and combining it with this medication may lead to an additive effect. This combination could increase the chance of experiencing symptoms like dizziness, lightheadedness, or fainting.

Official Storage and Disposal Requirements

Based on official regulatory documents, the following conditions must be met to maintain the stability and integrity of Fedaloc SR slow-release tablets.

Storage Condition	Requirement
Temperature	Store at or below 25 C.
Protection	Protect from both light and moisture.
Packaging	Keep the container tightly closed, and keep the blister strips in the outer carton.
Handling	Swallow tablets whole. Do not break, crush, chew, or divide the slow-release tablets.

Disposal Instructions:

Disposal must follow specific labeling instructions or official drug take-back programs. If take-back options are unavailable, mix the medicine with an undesirable substance (such as kitty litter or coffee grounds) in a sealed bag before placing it in household trash. To protect privacy, scratch out all identifying information on the prescription label. This medicine should not be flushed down a sink or toilet.